.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,538,739

« Back to Dashboard

Summary for Patent: 5,538,739

Title: Sustained release formulations of water soluble peptides
Abstract:The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.
Inventor(s): Bodmer; David (Klingnau, CH), Fong; Jones W. (Parsippany, NJ), Kissel; Thomas (Staufen, DE), Maulding, Jr.; Hawkins V. (Mendham, NJ), Nagele; Oskar (Sissach, CH), Pearson; Jane E. (Ogendensburg, NJ)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:07/643,880
Patent Claim Types:
see list of patent claims
Compound; Formulation;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,538,739

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Hungary3974/90Jun 25, 1990
United Kingdom9016840Aug 01, 1990

International Patent Family for Patent: 5,538,739

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria402503<disabled in preview>
Austria406225<disabled in preview>
AustriaA144090<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc